

Ref. No: 2141
Date: 03/11/25
Subject: Biologics Dermatology

REQUEST & RESPONSE

How many new patients were treated for Psoriasis by the Trust's Dermatology Department in the latest 3-month period of June, July and August (or the latest 3 months available) with the treatments I have provided below?

Please can you define a "new patient" as a patient who has received any of the treatments listed below for the first time. If a patient received any of the below treatments before the 1st of June 2025, they can be classed as a new patient for the purposes of this question.

- Adalimumab [Humira] <5
- Adalimumab [All Biosimilars] <5
- Etanercept [Enbrel] 0
- Etanercept [All Biosimilars] 0
- Infliximab [Remicade] 0
- Infliximab [All Biosimilars] 0
- Ustekinumab [Stelara] 0
- Ustekinumab [All Biosimilars] <5
- Apremilast [Otezla] 0
- Bimekizumab [Bimzelx] 0
- Brodalumab [Kyntheum] 0
- Certolizumab [Cimzia] 0
- Deucravacitinib [Sotyktu] 0
- Dimethyl Fumarate [Skilarence] 0
- Guselkumab [Tremfya] <5
- Ixekizumab [Taltz] <5
- Risankizumab [Skyrizi] 10
- Secukinumab [Cosentyx] 0
- Spesolimab [Spevigo] 0
- Tildrakizumab [illumetri] 0

<5

Due to the low number of patients which is less than five for the period, the Trust is withholding the actual number under section 40 – Personal

Information of the Freedom of Information Act due to likelihood of identification of the individual(s).

If the requestor or any other member of the general public can, on the balance of probabilities, identify individuals by cross-referencing the anonymised data with other information that was available to them, then the information is personal data and exempt from disclosure under the Act.